Triplet induction, autologous HSCT, lenalidomide maintenance extend PFS in multiple myeloma

CHICAGO — Lenalidomide, bortezomib and dexamethasone plus autologous stem cell transplantation and lenalidomide-based maintenance conferred a significant PFS benefit among patients with newly diagnosed multiple myeloma.
However, no OS benefit had been observed at the time of data cutoff, according to results of the phase 3 DETERMINATION trial presented during ASCO Annual Meeting and published simultaneously in The New England Journal of Medicine.
“We sought to explore the impact of a triplet therapy in a cohort of newly diagnosed, younger-aged patients and how to best use transplant

CHICAGO — Lenalidomide, bortezomib and dexamethasone plus autologous stem cell transplantation and lenalidomide-based maintenance conferred a significant PFS benefit among patients with newly diagnosed multiple myeloma.
However, no OS benefit had been observed at the time of data cutoff, according to results of the phase 3 DETERMINATION trial presented during ASCO Annual Meeting and published simultaneously in The New England Journal of Medicine.
“We sought to explore the impact of a triplet therapy in a cohort of newly diagnosed, younger-aged patients and how to best use transplant